Spectrum and risk factors for invasive candidiasis and non-Candida fungal infections after liver transplantation

Chinese Medical Journal

Volumn 121, Issue 7, 2008, Pages 625-630

  Shi, Shao Hua ^a   Lu, An Wei ^a   Shen, Yan ^a   Jia, Chang Ku ^a   Wang, Wei Lin ^a   Xie, Hai Yang ^b   Zhang, Min ^a   LIang, Ting Bo ^a   Zheng, Shu Sen ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Aspergillosis; Candidiasis; Liver transplantation; Risk factors

Indexed keywords

COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PENTAMIDINE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TACROLIMUS; TIMENTIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BACTERIAL INFECTION; BRAIN DISEASE; CANDIDA; CHRONIC HEPATITIS; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION RISK; INFECTION SENSITIVITY; INVASIVE CANDIDIASIS; KIDNEY DYSFUNCTION; LAPAROTOMY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOSIS; OROPHARYNX CANDIDIASIS; PATHOGENESIS; PERIOPERATIVE PERIOD; POSTOPERATIVE INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURGICAL MORTALITY; SURGICAL RISK; CANDIDIASIS; CRYPTOCOCCOSIS; LUNG MYCOSIS; MIDDLE AGED;

ADULT; ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCOSIS; FEMALE; HUMANS; LIVER TRANSPLANTATION; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 46449100189     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200804010-00010     Document Type: Article

References (31)

1. Paya CV. Prevention of fungal and hepatitis virus infections in liver transplantation. Clin Infect Dis 2001; 33 Suppl 1: S47-S52.
2. Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000; 31: 545-553.
3. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004; 39 Suppl 4: S200-S206.
4. Husain S, Tollemar J, Dominguez EA, Baumgarten K, Humar A, Paterson DL, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003; 75: 2023-2029.
5. Briegel J, Forst H, Spill B, Haas A, Grabein B, Haller M, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14: 375-382.
6. Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine 1988; 67: 132-143.
7. Nieto-Rodriguez JA, Kusne S, Mañez; R, Irish W, Linden P, Magnone M, et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 1996; 223:70-76.
8. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 729-737.
9. Singh N, Avery RK, Munoz P, Pruett TL, Alexander B, Jacobs R, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver-transplant recipients. Clin Infect Dis 2003; 36: 46-52.
10. Fortún J, Martín-Dávila P, Moreno S, De Vicente E, Nuño J, Candelas A, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8: 1065-1070.
11. Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RI, Lewis WD, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644-652.
12. Patel R, Portela D, Badley AD, Harmsen WS, Larson-Keller JJ, Ilstrup DM, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62: 926-934.
13. Kusne S, Torre-Cisneros J, Mañez R, Irish W, Martin M, Fung J, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992; 166: 1379-1383.
14. Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002; 73: 63-67.
15. Bernuau J, Rueff B, Benhamou JP, Fulminant and subfulminant liver failure: definition and causes. Semin Liver Dis 1986, 6: 97-106.
16. Pappas PG, Andes D, Schuster M, Hadley S, Rabkin J, Merion RM, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant 2006; 6: 386-391.
17. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006; 12: 850-858.
18. Singh N, Gayowski T, Singh J, Yu VL. Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis 1995; 20: 617-620.
19. Castaldo P, Stratta RJ, Wood RP, Markin RS, Patil KD, Shaefer MS, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126: 149-156.
20. Ma YK, Yan LN, Li B, Lu SC, Huang AH, Wen TF, et al. Diagnosis and treatment of bacterial pneumonia in liver transplantation recipients: report of 33 cases. Chin Med J 2005; 118: 1879-1885.
21. Wiesner RH, Hermans PE, Rakela J, Washington JA 2nd, Perkins JD, DiCecco S, et al. Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation 1988; 45: 570-574.
22. Kusne S, Tobin D, Pasculle AW, Van Thiel DH, Ho M, Starzl TE. Candida carriage in the alimentary tract of liver transplant candidates. Transplantation, 1994; 57: 398-402.
23. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-1534.
24. Inoue S, Wirman JA, Alexander JW, Trocki O, Cardell RR. Candida albicans translocation across the gut mucosa following bum injury. J Surg Res 1988; 44. 479-492.
25. Consensus Development Conference Panel. Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Ann Intern Med 1994; 121: 62-70.
26. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999; 78: 123-138.
27. Singh N, Arnow PM, Bonham A, Dominguez E, Paterson DL, Pankey GA, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64: 716-720.
28. Hellinger WC, Bonatti H, Yao JD, Alvarez S, Brumble LM, Keating MR, et al. Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation. Liver Transpl 2005; 11: 656-662.
29. Vilcheza RA, Fung J, Kusnea S. Cryptococcosis in organ transplant recipients: an overview. Am J Transplant 2002; 2: 575-580.
30. Vilchez R, Shapiro R, McCurry K, Kormos R, Abu-Elmagd K, Fung J, et al. Longitudinal study of cryptococcosis in adult solid-organ transplant recipients. Transpl Int 2003; 16: 336-340.
31. Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Cryptococcal meningitis: an analysis among 5521 consecutive organ transplant recipients. Transpl Infect Dis 2002; 4: 183-188.